EPO and Pure red cell aplasia: Such adverse reaction appeared associated with an increased immunogenicity of the biologic product, with induction of anti-erythropoietin antibodies and pure red-cell aplasia in treated patients.48 The term biosimilar should, therefore, be reserved for products developed in a comparative fashion, according to strict regulatory standards.7,8,11,12